LCZ696 not checked
Advanced Accelerator Applications
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
6 active
8 in total · 8 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Neoplasms
- Main trialPhase 1/2
- “First in Human (FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), distribution, radiation dosimetry, and anti-tumor activity of \[177Lu\]-NeoB in patients with advanced solid tumors known to overexpress GRPR and with \[68Ga\]-NeoB lesion uptake.”In the company’s words, NCT03872778 on ClinicalTrials.gov
- Other names
- sacubitril · valsartan
Other drugs for Neoplasms
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 7 Jan 2025 | [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake | |
| Phase 4Authorised | not given | Timely recovery after subclinical heart failure | |
| Phase 4Authorised | not given | Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy: (REMOVE) | |
| Phase 3Authorised | not given | Evaluation of the Efficacy of Valsartan in Slowing Down Aortic Root Dilatation in Children and Young Adults with Marfan-type Heritable Thoracic Aortic Diseases – Valsar-TAD, a randomised, double-blind, placebo-controlled multicentre trial | |
| Phase 4Authorised | not given | Blockade of the renin-angiotensin system in kidney transplant patients with the presence of renal progenitor cells in urine: randomized clinical trial. | |
| Phase 4Ended | not given | NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial | |
| Phase 4Authorised | not given | Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial) | |
| Phase 3/4Authorised | not given | Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026